Compass Pathways submits COMP360 psilocybin new drug application to FDA for treatment-resistant depression
Compass Pathways announced it has submitted a new drug application to the FDA for its COMP360 psilocybin for treatment-resistant depression (TRD). The FDA is now reviewing three psychedelic applications, after Resilient Pharmaceuticals resubmitted its MDMA for PTSD application this summer and Usona Institute filed its psilocybin for major depressive disorder (MDD) package more recently. Compass said its package includes data from more than 1,000 participants, and the company is targeting an H1 2027 launch.
Why it matters: With three psychedelic applications now before the FDA, the agency's next steps on COMP360 will show how it handles a package drawn from more than 1,000 participants.